A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
← catalyst calendarNCT07226882 · readout in 526 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
207actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-19 | actual | When the study began enrolling |
| Primary completion | 2028-01-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-27 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lyme Borreliosis
Interventions
- Biological: VLA15
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFGeometric Mean Concentration (GMC) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG)
measured At 1 month after the fourth VLA15 dose
Geometric Mean Fold Rise (GMFR) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations
measured Before the first dose to 1 month after the fourth VLA15 dose
Sero-Response Rate Based on Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations.
measured Before the first dose to 1 month after the fourth VLA15 dose
Percentage of Participants With Local Reactions For Each Group
measured Within 7 days after each vaccination
Percentage of Participants With Systemic Events For Each Group
measured Within 7 days after each vaccination
Percentage of Participants With Adverse Events (AEs) For Each Group
measured Within 1 month after each vaccination
Percentage of Participants With Serious Adverse Events (SAEs) For Each Group
measured From the time the participant provides informed consent up to approximately 6 months after the last vaccination
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) For Each Group
measured From the time the participant provides informed consent up to approximately 6 months after the last vaccination
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed